Merck & Co (NYSE:MRK)‘s stock had its “buy” rating reaffirmed by investment analysts at TheStreet in a note issued to investors on Tuesday, AR Network reports.
The analysts wrote, “Merck (MRK) has been reiterated by TheStreet Ratings as a buy with a ratings score of B+. The company’s strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.”
Shares of Merck & Co (NYSE:MRK) traded down 0.09% during mid-day trading on Tuesday, hitting $47.845. 3,852,576 shares of the company’s stock traded hands. Merck & Co has a 52-week low of $40.02 and a 52-week high of $50.16. The stock’s 50-day moving average is $47.7 and its 200-day moving average is $47.24. The company has a market cap of $140.0 billion and a P/E ratio of 28.68.
Merck & Co (NYSE:MRK) last released its earnings data on Tuesday, July 30th. The company reported $0.84 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.82 by $0.02. The company had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $11.22 billion. During the same quarter in the prior year, the company posted $1.05 earnings per share. The company’s quarterly revenue was down 10.6% on a year-over-year basis.
Other equities research analysts have also recently issued reports about the stock. Analysts at Argus raised their price target on shares of Merck & Co from $52.00 to $54.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Separately, analysts at Goldman Sachs Group Inc. raised their price target on shares of Merck & Co to $54.00 in a research note to investors on Tuesday, October 1st. Finally, analysts at Goldman Sachs Group Inc. reiterated an “in-line” rating on shares of Merck & Co in a research note to investors on Monday, September 30th. They now have a $54.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and eleven have assigned a buy rating to the company’s stock. Merck & Co currently has an average rating of “Buy” and a consensus price target of $51.40.
Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.